A non-peer-reviewed study used CRISPR interference Perturb-seq to suppress 520 genes in primary mouse hematopoietic stem and progenitor cell cultures and resolve local transcriptional effects separately from shifts in cell-state abundance. The authors derived…
Biotech had an approval week that tested whether comparative human evidence still beats platform storytelling. Broad active-state RAS inhibition crossed from thesis to approved medicine when the FDA cleared Rasonque after a 500-patient randomized…
Vivace Therapeutics named Craig Gibbs as chief executive officer and appointed Ellen Lubman as chief business and strategy officer, formalizing a leadership transition from founder Sofie Qiao as the company advances VT3989 toward a…
Seoul National University researchers published a prime-editing-derived DNA assembly system in Nature Biotechnology that enables kilobase-scale gene insertion and megabase-scale excision without generating double-strand breaks, demonstrating functional CD19 CAR-T cell engineering as a proof-of-concept…
Researchers at Rice University and MD Anderson Cancer Center identified a class of PS127 compounds through a function-based cheminformatic screen that induce autophagy, disrupt redox homeostasis via glutathione reductase, and trigger apoptosis in acute…
Genentech licensed DualityBio’s DUPAC antibody-drug conjugate platform in a deal worth $45 million upfront and more than $1 billion in potential milestones, gaining rights to a novel-payload ADC technology still in early, DualityBio-led preclinical-to-Phase…
Cytokinetics’ ACACIA-HCM trial met both co-primary endpoints for aficamten, marketed as MYQORZO for obstructive hypertrophic cardiomyopathy, in patients with non-obstructive hypertrophic cardiomyopathy, positioning the company to pursue a supplemental filing that would extend the…
Spyre Therapeutics reported Week 12 results from the 143-patient Phase II SKYWAY-RA trial of the anti-TL1A antibody SPY072 in moderate-to-severe rheumatoid arthritis. The low-dose arm met the primary DAS28-CRP endpoint and showed nominally significant…
ProFound Therapeutics received a Gates Foundation funding commitment of up to $35 million, including $20 million initially, to identify biomarkers, drug targets and potential protein therapeutics for preeclampsia and eclampsia. The program will combine…
A 245-patient real-world study found that immune effector cell-associated hematotoxicity (ICAHT) after BCMA-directed CAR-T therapy was less frequent when treatment occurred after one to three prior lines rather than four or more lines, but…
